|
Daniel's Biotech Briefing
Vedanta Biosciences raised $60 million, Helfie AI added former Apple, Airbnb, and Meta executives to its board, and MoonLake faced questions over autoimmune drug data.
The top 10 stories from Tue Aug 11, 2026 07:09 AM to Wed Aug 12, 2026 07:05 AM
Generated August 12, 2026 at 7:05 AM
|
|
|
#1 Epicrispr secures $90M after early data on epigenetic FSHD treatment Published 2026-08-11 Epicrispr Biotechnologies raised $90 million in a Series C round after sharing early data on a potential epigenetic treatment for facioscapulohumeral muscular dystrophy. Covered by: endpoints.news, fiercebiotech.com |
#2 STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate? Published 2026-08-11 MoonLake Immunotherapeutics reported “positive” results for an autoimmune drug candidate, but the article alleges the data release is unclear and repeatedly problematic. Covered by: statnews.com |
#3 With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development Published 2026-08-12 The article claims AI is increasingly used in drug development, including in pharma R&D and investment markets, to accelerate and reshape how new drugs are developed. Covered by: biospace.com |
#4 Helfie AI Appoints Heavyweight Tech and Governance Leaders to its Board of Directors Published 2026-08-12 Helfie AI appointed former Apple and Airbnb executive Patrick Gates and ex-Meta executive Sunita Parasuraman as non-executive directors to its board. Covered by: prnewswire.com |
#5 Galvanize Therapeutics® Announces First Commercial Procedures Using the New Aliya® EX System Published 2026-08-12 Galvanize Therapeutics announced its first commercial procedures using the Aliya EX pulsed electric field system, expanding interventional capability across percutaneous and endoscopic approaches. Covered by: prnewswire.com |
#6 Vaderis Closes Series B Round To Fund Phase III HHT Asset Engasertib Published 2026-08-11 Vaderis raised $152 million in venture capital and started the Phase III HEROIC trial of engasertib for hereditary hemorrhagic telangiectasia, which currently has no FDA-approved therapies. Covered by: insights.citeline.com, prnewswire.com, prnewswire.com, fiercebiotech.com |
#7 Vedanta Biosciences Nabs $60M Financing Round Published 2026-08-11 Vedanta Biosciences, based in Cambridge, Massachusetts, secured $60 million in funding. Covered by: vcnewsdaily.com |
#8 Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update Published 2026-08-11 Immunic, Inc. reported second-quarter 2026 financial results and announced leadership changes, including appointments for CEO, CMO, and board chair, to support clinical development and NDA readiness. Covered by: prnewswire.com |
#9 July FDA approvals deliver first products for three biotechs Published 2026-08-11 In July, the FDA approved six novel drugs, including the first oral PCSK9 inhibitor, delivering initial products for three biotech companies. Covered by: biocentury.com |
#10 Did Exelixis use a 'trivial' modification to its cash cow to product hop past a patent cliff? These researchers think so Published 2026-08-11 Exelixis CEO Michael Morrissey reported 2025 results earlier this year, highlighting cabozantinib’s major role in funding the company and supporting its stock. Covered by: endpoints.news |
